Aiming to boost its immune-oncology pipeline, Coherus BioSciences (Nasdaq: CHRS) today announced it will acquire Surface Oncology (Nasdaq: SURF), with the news sending the share of the latter roaring up more than 16% to $0.86. Coherus stock, on the other hand, fell as much as 18.2% to $4.41.
Surface Oncology is a clinical-stage I-O company developing next-generation immunotherapies that target the tumor microenvironment.
The Surface acquisition adds two differentiated clinical stage assets to Coherus’ novel I-O pipeline: SRF388, a novel interleukin (IL)-27-targeted antibody currently being evaluated in Phase II clinical trials in lung cancer and liver cancer, and SFR114, a CCR8-targeted antibody currently in a Phase I/II study as a monotherapy in patients with advanced solid tumors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze